Publicaciones en colaboración con investigadores/as de University of Lille Nord de France (62)

2024

  1. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  2. Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 4, pp. 793-822

  3. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14

  4. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023

    Transplant Infectious Disease, Vol. 26, Núm. 1

2023

  1. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

    Chest, Vol. 163, Núm. 3, pp. 586-598

  2. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  3. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    HemaSphere, Vol. 7, Núm. 9, pp. E942

  4. Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 4, pp. 1134-1146

  5. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE)

    World Allergy Organization Journal, Vol. 16, Núm. 3

2022

  1. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT

    Bone Marrow Transplantation, Vol. 57, Núm. 5, pp. 817-823

  2. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial

    European Heart Journal, Vol. 43, Núm. 29, pp. 2783-2797

  3. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

    Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846

  4. Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    The American journal of gastroenterology, Vol. 117, Núm. 5, pp. 818

  5. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial

    European Journal of Neurology, Vol. 29, Núm. 3, pp. 790-801

  6. Improving the reporting of allergic adverse events during immunotherapy for food allergy

    Journal of Allergy and Clinical Immunology

  7. Managing food allergy: GA2LEN guideline 2022

    World Allergy Organization Journal, Vol. 15, Núm. 9

  8. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials

    Annals of Allergy, Asthma and Immunology, Vol. 129, Núm. 6, pp. 758-768.e4

  9. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

  10. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    American Journal of Gastroenterology, Vol. 117, Núm. 2, pp. 301-310

2021

  1. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 5, pp. 1047-1055